🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for pMMR/MSS Locally Advanced Rectal Cancer

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. NCT07595276Phase 31 site📍 Guangzhou Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo®, Erbitux® Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer NCT07528209Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Pucotenlimab combine with CAPOX, CAPOX Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK） NCT07005570Phase 21 site📍 Guangzhou Dechang Diao · Tests: Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab, S… Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) NCT06923345Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Reduced CTV, Conventional CTV Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer NCT07686640Phase 31 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Short-course Radiotherapy, SCRT, Toripalimab mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC NCT06791512Phase 31 site📍 Guangzhou Jun Huang · Tests: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer NCT07458529Phase 21 site📍 Beijing Seventh Medical Center of PLA General Hospital · Tests: CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Experimental, Control Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726Phase 21 site📍 Hangzhou Zhejiang University · Tests: Serplulimab, Capecitabine, Oxaliplatin, Celecoxib Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT) NCT07026422Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer NCT07674732Phase 21 site📍 Guangzhou Dechang Diao · Tests: Short-course Radiotherapy plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chem… Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer NCT07448142Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial NCT07622771Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherap… Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. NCT06911684Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy, lparomlimab and Tuvonra… A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer NCT07527026Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Camrelizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy